Free Trial

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 44 +0.50 (+1.15%)
(As of 12:17 PM ET)

SPEC vs. BVC, AKR, CNSL, ODX, CTEC, AMS, TSTL, FARN, BXP, and AVCT

Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), Tristel (TSTL), Faron Pharmaceuticals Oy (FARN), Beximco Pharmaceuticals (BXP), and Avacta Group (AVCT). These companies are all part of the "medical" sector.

INSPECS Group vs.

BATM Advanced Communications (LON:BVC) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.

42.4% of BATM Advanced Communications shares are owned by institutional investors. Comparatively, 67.8% of INSPECS Group shares are owned by institutional investors. 26.2% of BATM Advanced Communications shares are owned by insiders. Comparatively, 25.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BATM Advanced Communications has a net margin of -0.21% compared to INSPECS Group's net margin of -2.11%. BATM Advanced Communications' return on equity of -0.17% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-0.21% -0.17% 0.58%
INSPECS Group -2.11%-3.95%0.45%

BATM Advanced Communications pays an annual dividend of GBX 1 per share and has a dividend yield of 5.5%. INSPECS Group pays an annual dividend of GBX 1 per share and has a dividend yield of 2.3%. INSPECS Group pays out -32.6% of its earnings in the form of a dividend.

BATM Advanced Communications has higher earnings, but lower revenue than INSPECS Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£122.70M0.65£2.51MN/AN/A
INSPECS Group£195.14M0.23-£4.11M-£3.07-14.33

BATM Advanced Communications has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 2.22, meaning that its stock price is 122% more volatile than the S&P 500.

In the previous week, BATM Advanced Communications' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
BATM Advanced Communications Neutral
INSPECS Group Neutral

BATM Advanced Communications received 185 more outperform votes than INSPECS Group when rated by MarketBeat users. However, 100.00% of users gave INSPECS Group an outperform vote while only 49.48% of users gave BATM Advanced Communications an outperform vote.

CompanyUnderperformOutperform
BATM Advanced CommunicationsOutperform Votes
190
49.48%
Underperform Votes
194
50.52%
INSPECS GroupOutperform Votes
5
100.00%
Underperform Votes
No Votes

Summary

BATM Advanced Communications beats INSPECS Group on 9 of the 14 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£44.74M£2.49B£5.04B£1.41B
Dividend Yield2.00%2.01%4.81%11.77%
P/E Ratio-14.33319.08133.081,563.33
Price / Sales0.23132.291,120.44297,901.50
Price / Cash1.63131.2140.6333.22
Price / Book0.442.924.752.87
Net Income-£4.11M£84.03M£118.34M£153.33M
7 Day Performance1.15%-1.86%11.87%18.10%
1 Month Performance-24.14%-1.58%11.93%18.15%
1 Year Performance-47.93%-5.73%31.39%23.31%

INSPECS Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 44
+1.1%
N/A-49.1%£44.74M£195.14M-14.331,673Gap Up
BVC
BATM Advanced Communications
N/AGBX 19
+2.9%
N/A-6.3%£82.88M£122.70M2,800.00980
AKR
Akers Biosciences
N/AGBX 57.50
flat
N/A+0.0%£21.64M£2.32M-0.44120
CNSL
Cambridge Nutritional Sciences
N/AGBX 2.86
-6.4%
N/AN/A£6.80M£9.77M-362.103,200Gap Down
ODX
Omega Diagnostics Group
N/AGBX 2.20
flat
N/AN/A£5.23M£7.55M-220.0091Gap Down
CTEC
ConvaTec Group
2.4802 of 5 stars
GBX 227.60
-3.1%
GBX 301.67
+32.5%
-5.6%£4.67B£2.20B3,913.3310,000
AMS
Advanced Medical Solutions Group
1.8425 of 5 stars
GBX 202.50
-1.5%
GBX 300
+48.1%
-8.0%£434.46M£131.11M4,031.2410
TSTL
Tristel
N/AGBX 376
-3.6%
N/A-14.6%£179.16M£39.49M3,000.00208
FARN
Faron Pharmaceuticals Oy
N/AGBX 167.70
+1.6%
N/A-49.3%£175.45M£-725,000.00-531.2534
BXP
Beximco Pharmaceuticals
N/AGBX 37.70
+7.7%
N/A-13.2%£168.18M£43.08B471.255,500Gap Up
AVCT
Avacta Group
N/AGBX 46.25
+6.5%
N/A-59.1%£165.71M£22.62M-513.33120Negative News

Related Companies and Tools


This page (LON:SPEC) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners